New drug HDM2020 targets tough lung cancer in early trial

NCT ID NCT07638891

Recruiting now Disease control Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called HDM2020 in 150 people with advanced squamous non-small cell lung cancer. The drug is designed to target a protein on cancer cells and deliver a chemotherapy agent directly to them. The main goals are to check if the drug is safe and tolerable, and to see if it can shrink tumors or slow cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HDM2020 (a drug that targets FGFR2b and delivers a chemotherapy agent directly to cancer cells)
What this could lead to: If this drug proves safe and effective, it could offer a new treatment option for people with advanced squamous non-small cell lung cancer.
What could go wrong: This is an early Phase 1 trial, so the drug may not work or could have unexpected side effects. Results are preliminary and need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SQUAMOUS NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Guangdong Provincial People's Hospital
RECRUITING

Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.